Osimertinib has been approved for use in patients with metastatic NSCLC harboring an exon 19 deletion or exon 21 L858R mutation and for patients with a T790M resistance mutation who have demonstrated disease progression after receiving an earlier generation EGFR-TKI. Here, EGFR is linked to non-small cell lung carcinoma.